Reports Q4 revenue $170.7M, consensus $156.8M. “We closed out the year with an exceptional quarter and a strong selling season, driving our highest win rates to date and greatest number of eligible lives added in any year,” said Daniel Perez, Co-Founder and CEO, Hinge Health (HNGE). “Our commercial momentum, combined with expanding margins and strong cash generation, gives us confidence in our ability to continue automating care delivery, sustain our position as a leader in digital musculoskeletal care, and drive attractive growth and increased margins in 2026.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health, Inc. options imply 9.7% move in share price post-earnings
- Hinge Health price target lowered to $59 from $66 at Stifel
- Reaffirming Buy on Hinge Health: Strong Win Rates, Sustained Growth, and Limited Competitive Threats Support $65 Target
- Evercore ISI sees limited impact to Hinge from Sword Health-Kaia Health deal
- Darden upgraded, Trade Desk downgraded: Wall Street’s top analyst calls